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Trends
New ﬁndings suggest that it is short-
sighted to limit the classiﬁcation of
mast cells to two subtypes; indeed,
each speciﬁc tissue has a unique mast
cell type that differs signiﬁcantly from
those of other tissues.
Mast cells continuously sample the
microenvironment, working to main-
tain tissue homeostasis and contribute
immediately to the immune response
to non-self-antigens.
A network of activating and inhibitoryNovel Insights into Mast Cell Biology
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Mast cells are evolutionarily ancient cells, endowed with a unique develop-
mental, phenotypic, and functional plasticity. They are resident cells that
participate in tissue homeostasis by constantly sampling the microenviron-
ment. As a result of their large repertoire of receptors, they can respond to
multiple stimuli and selectively release different types and amounts of media-
tor. Here, we present and discuss the recent mast cell literature, focusing on
studies that demonstrate that mast cells are more than a switch that is turned
‘off’ when in the resting state and ‘on’ when in the degranulating state. We
propose a new vision of mast cells in which, by operating in a ‘rheostatic’
manner, these cells ﬁnely modulate not only immune responses, but also the
pathogenesis of several inﬂammatory disorders, including infection, autoim-
munity, and cancer.stimuli can modulate mast cell activity.
A mast cell is more than a switch that is
turned ‘off’ when in the resting state
and ‘on’ when needed; instead, mast
cells show a range of modulated
responses that contribute to the ﬁne-
tuning of the immune response.
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Mast cells are long-lived, tissue-resident, innate immune cells that are found primarily in sites
that are in close connection with the external environment, where they have a role in host
defense against parasites [1]. However, their functions are not limited to pathogen removal:
they also take part in wound healing [2] and maintenance of tissue homeostasis [3], and are
involved in chronic inﬂammation [4,5] as well as autoimmune diseases [6,7] and cancer
development [8]. Different local tissue activities require mast cells to be equipped with a range
of receptors that sample diverse microenvironments, allowing the immune system to mount a
speciﬁc response that depends on the stimulus [9]. Guided by molecular signals exchanged
with the microenvironment, mast cells in different locations adapt their repertoire of receptors
and ligands to meet the diverse functional requirements of their host tissue, highlighting their
incredible cell plasticity [10]. In this review, we discuss our growing knowledge of mast cell
versatility and provide an updated vision of this underestimated type of immune cell.
Mast Cell Development, Tissue Migration, and Plasticity
Although mast cells are generally assumed to be long-lived cells in the periphery, they are
continually replenished by rare blood-circulating precursors (CD34+, CD13+, c-kit+, and
FceRI) released from the bone marrow into the blood stream. They are recruited via venules
and mature into one of several mast cell subsets (see below) during their migration towards their648 Trends in Immunology, September 2017, Vol. 38, No. 9 http://dx.doi.org/10.1016/j.it.2017.04.001
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ﬁnal location within the tissue. Although the signals that lead to the migration and localization of
mast cells are not yet completely understood, analysis of the chemokine receptors involved can
provide useful information. Indeed, mast cells express numerous surface receptors for many
ligands with chemoattractant properties [11,12], including CXCR2, CXCR4, CCR3, CX3CR1,
CCR5 [13,14], c-Kit [15,16], and integral membrane-bound G-protein-coupled receptors
(GPCRs), which bind and respond to eicosanoids [17–19]. However, it is unclear whether
these chemokine receptors lead to the selective tissue homing of mast cells or whether they are
involved in cell maturation. CCR3 is present on the cell surface during mast cell maturation and,
because it binds to CCL11, CCL24, and CCL26, it might have a role in tissue cell homing [13].
Additionally, CCL11 acts synergistically with stem cell factor (SCF) to increase the number of
embryonic mast cell progenitors [20], suggesting that chemokines also have a role in mast cell
development. Mast cells are the only terminally differentiated hematopoietic cells that express
the c-Kit receptor. SCF binds to this receptor on immature and mature mast cells, activating
them and inducing their chemotaxis and survival at steady state in mice [21,22]. It is likely that
mast cell precursors are attracted by SCF produced by ﬁbroblasts and endothelial cells for
entry into peripheral tissues. However, the tissue localization of mast cells requires tissue-
speciﬁc signals. In fact, the interaction of the a4b7 integrin expressed on mast cell progenitors
with the mucosal addressin cellular adhesion molecule-1 (MAdCAM-1) is required for homing to
the mouse small intestine [23] and this process is speciﬁcally dependent on CXCR2, as
demonstrated by using CXCR2-deﬁcient mice, which are defective only in intestinal mast cells
[24]. Additionally, inﬂammatory mediators, such as leukotriene D4 (LTD4) and B4 (LTB4),
induce the passage of mast cell precursors across the endothelium into peripheral tissues
[25–27]. These studies indicate that different receptor–ligand pairs may be required for mast
cell entrance and terminal maturation into different peripheral tissues. Nevertheless, the precise
chemokines involved remain unclear, given that chemokine receptor expression varies greatly
among the in vivo subsets. In the periphery, tissue mast cells locate near blood and lymphatic
vessels, glands, smooth muscle, and nerves. In these sites, mast cell precursors can either
remain as a homeostatic pool or complete their differentiation process into mature mast cells
upon exposure to the local environment, a process that is also modulated by the genetic
background in different mice strains. Indeed, compared with the C57BL/6 strain, BALB/c mice
display higher levels of IL-5, IL-13, and CCL11 in the lung and show greater airway reactivity to
methacholine [28]. Additionally, circulating mast cell precursors were found to be more mature
in BALB/c than in C57BL/6 mice [29]. Thus, a real ‘circulating’ mast cell does not exist and,
therefore, this cell type can be considered only as a tissue-resident cell. Other nonterminally
differentiated immune cell types circulate in the blood but, in contrast to mast cell precursors,
they share some characteristics with their fully differentiated counterpart. Indeed, monocytes
actively patrol the vascular endothelium under homeostatic and inﬂammatory conditions [30]
and, together with circulating neutrophils, they store in their cytoplasmic granules cytokines
typically present in macrophages and activated neutrophils. Therefore, the lack of a circulating
mast cell is unique among the different cell types of the immune system, but should not be
considered a restriction. Indeed, the capacity of the mast cell to differentiate into a fully mature
and functional cell only within the tissue gives rise to an extremely heterogeneous population.
Classically, mast cells have been classiﬁed depending on their tissue distribution and granule
content. Based on the proteases produced, human mast cells have been categorized into
those that contain predominantly tryptase (MCT) or chymase (MCC) or both (MCTC) [31]. The
two proteases have distinct substrate speciﬁcities and are part of the large array of effector
molecules contained in mast cell granules. A similar scenario can be observed in mice, where
mast cell populations of connective or serosal tissues (CTMC) contain abundant heparin in their
granules, while mucosal mast cells (MMC) have little or no heparin. However, the factors that
can regulate the molecules expressed and stored in these granules will subsequently modulate
the functions exerted by mast cells [32]. Thus, it is possible to argue that tissue-speciﬁc mastTrends in Immunology, September 2017, Vol. 38, No. 9 649
cells display differences in their granule content, cytokine expression pattern, and tissue-
speciﬁc receptors that provide context-related functions to the cell. In support of this consid-
eration, a recent transcriptional analysis carried out by Dwyer and colleagues on 14 lymphoid
and myeloid cell populations identiﬁed the mast cell as the most transcriptionally variable cell
type of the immune system [33]. The authors demonstrated that murine mast cells puriﬁed from
different tissues shared a ‘mast cell-speciﬁc’ transcriptional signature of more than 100 genes
and also showed tissue-speciﬁc regulation of their transcriptomes [33]. Among these, there
were genes encoding serine proteases (MCPT) and metalloproteases (ADAMTS), and mole-
cules required for the generation of preformed and newly synthetized mediators [5-lypoxyge-
nase (ALOX5) and oxidized lipoprotein receptor (ORL1)], as well as genes encoding cytokines
(IL3) and adhesion molecules (CD59a and ITGB2). Similarly, an in silico data analysis performed
by Saito and coworkers provided evidence of a different gene expression proﬁle depending on
the speciﬁc environmental context [34]. Interestingly, the upregulation of speciﬁc mRNAs
associated with the MCTC phenotype (CMA1, HEY1, and C5R1) was observed in tonsil-
and skin-derived but not in lung-derived mast cells.
Based on the above results, the historical classiﬁcation of mast cells based on their tissue
distribution and granule content can be now revisited based on insights from gene expression
proﬁle analyses (Table 1). The further extension and validation of differential gene expression
analyses of both human and murine mast cell subsets could help to better deﬁne this
multifaceted cell and to clarify its speciﬁc role in different pathophysiological contexts.
Rheostatic Functions of Mast Cells
Mast cells have long been considered critical effector cells during IgE-mediated allergic disease
and their role has consequently been linked to massive degranulation with ‘all or nothing’ effects
on the immune response. This commonplace interpretation has restricted our view of the
function of mast cells only to promoting or suppressing the immune response in relation to, or
as a consequence of, cell activation, following a speciﬁc stimulation. However, given their
continuous sampling of the microenvironment, ‘resting’ mast cells do not exist. Indeed, the
mast cell can be considered as a rheostat that can modulate the intensity of its response based
on the signals it receives from the microenvironment (Figure 1).
In a physiological context, mast cells have primarily a homeostatic function. For example, given
their association with blood vessels, lymphatics, epithelial surfaces, and smooth muscle, these
cells release mediators to modulate ﬂuid ﬂow, permeability, secretion, and contraction in many
sites [35,36]. Numerous papers have described the ability of mast cells to control, expand, and
inﬂuence the activities of regulatory and effector B [37,38] and T lymphocytes [39,40] as well as
the activities of innate immune cells (myeloid-derived suppressor cells, eosinophils, and stromal
cells) [9] by direct crosstalk and, importantly, in the absence of external activation signals and
classical degranulation (Figure 1A). Co-stimulatory molecules belonging to the TNF/TNFR
families (CD40L, OX40L, 4-1BB, GITR, CD153, Fas, TRAIL-R, and HVEM) are implicated in
these interactions [41–43]. Notably, these receptors and ligands are constitutively expressed
by mast cells and their levels of expression are not signiﬁcantly affected by mast cell activation
[9,43]. Moreover, under resting conditions (i.e., in the absence of speciﬁc triggering and,
therefore, of ‘classical’ exocytosis), mast cells incessantly communicate with the microenvi-
ronment via two elegant secretion mechanisms, namely piecemeal degranulation (PMD) and
exosome release [32,44]. PMD has been principally described in basophils, mast cells, and
eosinophils, and comprises the gradual and prolonged emptying of cytoplasmic secretory
granules via vesicular transport, in the absence of direct granule-to-plasma membrane fusion
events [45]. One of the ﬁrst demonstrations of PMD in mast cells dates to the early 1990s, when
the slow release of mast cell granule content was described in the eyelid lesions of IL-4
transgenic mice [46]. Since then, mast cells functioning via PMD have been detected in several650 Trends in Immunology, September 2017, Vol. 38, No. 9
Table 1. Classiﬁcation of Human and Murine Mast Cells Based on Anatomical Localization, Granule Composition, and Differential Gene
Expressiona
Organ/Tissue MC subtype Granule composition Upregulated genes Downregulated genes Refs
Mouse
Trachea MMC Hist; MMCP1-2; chondroitin sulfate E Cd34, Cd59, Lipf [33]
Esophagus MMC Hist; MMCP1-2; chondroitin sulfate E Cd34, Cd59, Mcpt1, Mcpt2 [33]
Tongue MMC Hist; MMCP1-2; chondroitin sulfate E Cd34, Cd59 [33]
Ear MMC Hist; MMCP1-2; chondroitin sulfate E
Skin CTMC Hist; 5-HT; MMCP-3,4,5,6; carboxypeptidase;
heparin
Cd59, Mrgprb8, Mrgprb13,
Adamts1, Adamts5, Il-3, Sox7
[33]
Cd34, Alox5. Alox5ap [33]
Peritoneum CTMC Hist; 5-HT; MMCP-3,4,5,6; carboxypeptidase;
heparin
Cd34, Itgb2, Bmp2 Cd59, Orl1 [33]
Human
Alveoli MCT Hist; tryptase; heparin CMA1 [34]
Bronchi MCT MCC Hist; tryptase; heparin; chymase
Tonsils MCTC Hist; tryptase; chymase; cathepsin G;
carboxypeptidase; heparin
C5R1, CMA1, HEY1 [34]
Nasal mucosa MCT Hist; tryptase; heparin
Nasal
submucosa
MCTC Hist; tryptase; chymase; cathepsin G;
carboxypeptidase; heparin
Intestinal
mucosa
MCT Hist; tryptase; heparin
Intestinal
submucosa
MCTC MCC Hist; tryptase; chymase; cathepsin G;
carboxypeptidase; heparin
Skin MCTC Hist; tryptase; chymase; cathepsin G;
carboxypeptidase; heparin
CMA1, HEY1 [34]
Conjunctiva MCTC Hist; tryptase; chymase; cathepsin G;
carboxypeptidase; heparin
Axillary lymph
nodes
MCTC Hist; tryptase; chymase; cathepsin G;
carboxypeptidase; heparin
Breast
parenchyma
MCTC Hist; tryptase; chymase; cathepsin G;
carboxypeptidase; heparin
aAbbreviations: 5-HT, 5-hydroxytryptamine; CTMT, connective mast cell; Hist, histamine; MCC, mast cell containing chymase; MCT, mast cell containing tryptase;
MCTC, mast cell containing tryptase and chymase; MMC, mucosal mast cell.other settings, such as in antral biopsies from patients with Helicobacter pylori ‘active’ gastritis
[47] and in the context of gastric carcinomas [48]. Interestingly, signs of PMD were observed
following mast cell interaction with different cell types, such as regulatory T cells [49] and
conjunctival epithelial cells [50]. The observation that mast cells could release exosomes is even
more recent. In 2001, the research group of Mécheri described for the ﬁrst time the ability of
bone marrow-derived mast cells (BMMC), peritoneal mast cells, and mast cell lines to consti-
tutively secrete exosomes [44]. These authors provided crucial evidence of the fact that mast
cells use these extracellular vesicles as sophisticated messengers with immunoregulatory
functions on B and T lymphocytes [44,51] and dendritic cells [52]. More recently, mast cell
exosomes were found to express CD40L [37] and OX40L [53] and to expand the pool of IL-10-
competent B cells [37] as well as to promote the proliferation and differentiation of Th2 cells [53].
Another recent study demonstrated that exosomes from IFN-a-treated mast cells contained a
cytoplasmic isoform of PLA2 (PLA2G4D) that can be transferred to neighboring CD1a-express-
ing cells, contributing to a CD1a-reactive T cell response in patients with psoriasis [54].Trends in Immunology, September 2017, Vol. 38, No. 9 651
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Figure 1. Schematic Representation of the Mast Cell As a Rheostat That Modulates the Type and Amplitude of the Immune Response. In the absence
of external stimulation, the homeostatic function that the mast cell exerts on innate and acquired immune cells, via cell–cell contact or the spontaneous release of soluble
mediators, is predominant (A). Following the activation by speciﬁc endogenous and exogenous signals, mast cells respond differently in terms of the amount, type, and
kinetics of mediator release (B). Strong mast cell activation causes massive and extended secretion of preformed and newly synthetized mediators that cause local and
systemic reactions (C). Representative examples of cellular partners, membrane-bound receptors and soluble mediators are reported. Abbreviations: CADM-1, cell
adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; LT, leukotrienes; PG, prostaglandins; TLR, Toll-like receptor; TNF, tumor necrosis
factor; VEGF, vascular endothelial growth factor.Nevertheless, mast cells are best known for the consequences deriving from the loss or release
of their granules upon activation by external signals. The triggering of one of the countless
receptors that a mast cell expresses on its surface results in the release of the proteases stored
in the cytosolic granules, in the secretion of neosynthesized lipid-derived mediators, and in the652 Trends in Immunology, September 2017, Vol. 38, No. 9
production and secretion of a wide variety of cytokines and chemokines. However, once again,
the mast cell stands out for its versatility, since it can respond differently in terms of the kinetics
of release, as well as in the quality and quantity of the mediators produced following a speciﬁc
signal (Figure 1B). The engagement of pattern recognition receptors, such as Toll-like receptors
(TLRs), results in a selective mast cell response, with the secretion of a distinct and speciﬁc
array of cytokines and chemokines, rather than in the release of histamine. Indeed, when
stimulated with peptidoglycan, murine BMMC released TNF-a, IL-4, IL-5, IL-6, and IL-13, but
not IL-1b. By contrast, lipopolysaccharide (LPS)-treated BMMC secreted TNF-a, IL-1b, IL-6,
and IL-13, but not IL-4 or IL-5. Moreover, while TLR2 stimulation elicited degranulation,
engagement of TLR4 did not [55]. In addition, several membrane receptors for endogenous
molecules can also evoke a mast cell speciﬁc response. These include GPCRs that bind
inﬂammatory mediators (cytokines, complement fragments, and b-defensin), cationic ligands
(e.g., substance P), hormones, and neuropeptides (e.g., somatostatin, neurotensin, and
endothelin). The engagement of these GPCRs triggers the selective release of speciﬁc mol-
ecules, such as serotonin, IL-6, vascular endothelial growth factor (VEGF), and others, but not
of histamine [56]. Last but not least, mast cells are characterized by the presence of the high-
afﬁnity IgE receptor, FceRI, on their surface. This receptor is arguably the most-studied mast
cell activator and is thought of as a classical inducer of degranulation. However, it is also
possible to obtain different types of response as a result of the binding of this single receptor.
Indeed, the afﬁnity of the interaction between an IgE and its cognate antigen can vary,
inﬂuencing the size and stability of FceRI clusters and, consequently, the type of cell response
[57,58]. Antigens with either weak or low afﬁnity for IgE result in similar receptor phosphor-
ylation, although differences in receptor cluster size, mobility, distribution, and, therefore, mast
cell effector responses, are present. Indeed, low-afﬁnity stimulation boosted FceRI association
with the Src family kinase Fgr and shifted signals from the adapter LAT1 to the related adapter
LAT2 [57]. This, in turn, led to a response characterized by enhanced chemokine production,
but reduced degranulation and cytokine secretion (Figure 1B). This means that low-afﬁnity
interactions between IgE and its cognate antigen can elicit a cellular response without the
release of the classical preformed allergic mediators. By contrast, strong interactions between
an antigen and IgE cause the generation of highly dynamic FceRI clusters that form a tight
synapse-like structure [58]. This causes massive emptying of the granule content and promotes
the neosynthesis and release of mediators that orchestrate and sustain local and systemic
inﬂammatory reactions (Figure 1C). Recently, an elegant study by Gaudenzio and colleagues
compared the nature and kinetics of the degranulation induced by the engagement of FceRI
with the hapten dinitrophenyl (DNP) plus anti-DNP IgE and by the engagement of the GPCR
MRGPRX2 with substance P [59]. The authors demonstrated the existence of spatiotemporally
distinct patterns of mast cell degranulation and associated these differences with pathological
responses in vivo. FceRI-mediated mast cell activation was characterized by slower but
sustained Ca2+ inﬂux and inhibitor of kappa-B kinase (IKK-b) activation that allowed the fusion
of cytosolic granules to the plasma membrane and the formation of large granules. These were
slowly released and could be transported throughout the lymphatic circulation, inducing a
systemic immune response. By contrast, the activation of the mast cell by substance P induced
a rapid and transient release of individual small secretory granules responsible for the brief local
inﬂammatory reaction, developing a quick vascular reaction that also rapidly resolved [59].
All these differences in the timing, amount, and type of mediator released allow the mast cell to
intervene adequately in speciﬁc pathophysiological contexts, promoting the suppression or the
ampliﬁcation and diversiﬁcation of the immune response. This evidence has led us to propose
that, similarly to some other immune cells, mast cells also function as a rheostat and not simply
as an ‘on-off’ switch, as classically thought (Figure 1).Trends in Immunology, September 2017, Vol. 38, No. 9 653
Outstanding Questions
Mast cells are among the most phe-
notypically variable cells of the immune
system, because of their tissue-spe-
ciﬁc differentiation from a circulating
immature precursor and switch from
a pro-to anti-inﬂammatory phenotype.
How do these phenotypic changes
relate to those of other immune tis-
sue-resident immune cells?
Which are the physiological and the
pathophysiological roles of different
mast cell subtypes in the context of
diseases localized in different tissues?
In terms of therapeutic approaches,
how should we consider the different
responsiveness of the diverse mast cell
subtypes?
How might we use mast cells to
restore tissue homeostasis in patho-
logical conditions?Towards a Broader Understanding of Mast Cells Functions In Vivo
As underlined in this review, beyond their well-known role in IgE-mediated reactions, mast cells
contribute to the regulation of both innate and adaptive immune responses. Although this has
been a key area of investigation in the mast cell ﬁeld for the past three decades, little attention
has been paid to the role that these cells have in a physiological context or in interactions with
both immune and non-immune cells, which occur in the tissues and underpin tissue homeo-
stasis. A lesson is provided by the analysis of mast cell-deﬁcient mice, despite the caveats that
have been raised about these models and their reconstitution. Indeed, compared with wild-
type mice, mast cell-deﬁcient KitW-sh/W-sh (Wsh) mice or mast cell protease 4 deﬁcient (Mcpt4/
) mice present altered intestinal barrier functions, modiﬁcations in the intestinal morphology, as
well as dysregulated claudin-3 crypt expression [3]. Interestingly, the reconstitution of Wsh mice
with in vitro differentiated mast cells replenished the intestinal barrier function, which could be
because the lack of mast cells deprives the small intestine of a source of the anti-inﬂammatory
factor MCPT4, which degrades TNF-a [60–62]. Additionally, mast cells are important in the
differentiation of follicular helper T cells via ATP signaling [63], and have a role in IgA switch and
expression and in the overall homeostasis of gut bacteria [64,65]. Furthermore, the analysis of
unstimulated mast cell activities could be pivotal to our understanding of the importance of
mast cells in a physiological context. All the resting activities of mast cells can be inﬂuenced by
the mutual signaling exchange with the microenvironment. For example, the interaction
between mast cells and regulatory T cells sustains tolerance and sets a threshold of activation
for allergic or parasitic inﬂammation; however, mast cells are also able to rapidly revert their
behavior and polarize a strong immune response [40,66].
Further lessons on the regulatory activity of mast cells emerge from mastocytosis, a rare
disease in which there is uncontrolled cell activation dependent on a c-Kit mutation, or from
other diseases characterized by mast cell hyper-responsiveness. In these conditions, the
regulatory properties of mast cells, as well as the control of tissue homeostasis, are lost.
Indeed, the existence of a link between mastocytosis and the development of lymphoprolifer-
ative diseases of B cells (chronic lymphocytic leukemia, lymphoblastic leukemia, hairy cell
leukemia, monoclonal gammopathy of undetermined signiﬁcance, and plasma cell myeloma)
has been reported, supporting a key role of mast cells in B cell tumor development and growth
[67,68]. Moreover, it is suggestive that the increase in mast cell number and their functional
hyperactivation exacerbate their normal capacity to support the expansion of clonal popula-
tions and this is dependent on changes in the microenvironment [8]. In the context of solid
tumors, it has been reported that mast cell accumulation contributes to modeling the tumor
microenvironment (TME) during cancer progression [8]. In the TME, mast cell can release
mediators that support tumor growth, such as proteases (chymase), matrix-degrading
enzymes (MMP9), and angiogenic factors (VEGF), as well as inﬂammatory mediators (IL-6,
IL-1b, and TNF-a) that inhibit tumor progression [69]. In addition to the release of this multitude
of biologically active factors, mast cells were shown to interact with several cell types of the
TME, such as myeloid-derived suppressor cells [70], regulatory T cells [8,39], and the cancer
cell itself. It is via this mutual and continuous dialog with several cell types that mast cells shape
and model the TME [8].
Concluding Remarks
The overriding consideration of mast cells as cells responsible only for allergic reactions has
been largely overcome, given that new roles for this cell type within the immune system are
continuously being proposed. This will help provide a new perspective on an old cell that
appeared early during evolution [71], before other classical immune effector cells, such as
neutrophils [72], monocytes [72], and lymphocytes [73,74]. In this review, we have highlighted
two main concepts. The ﬁrst is the pivotal role of the microenvironment in guiding mast cell
tissue distribution, localization, and maturation, resulting in a multifaceted and versatile cell. The654 Trends in Immunology, September 2017, Vol. 38, No. 9
second concept concerns a new vision of a cell that never rests. Mast cells can be ﬁne-tuned by
a wide range of receptors and the production of mediators is speciﬁcally regulated by the
signals received. Under ‘resting conditions’, the mast cell uses this plastic repertoire to control
several immune cell functions in the absence of external activation. However, under appropriate
conditions, the mast cell uses the same repertoire to sense speciﬁc changes in the microenvi-
ronment and, consequently, to establish an appropriate reaction. Considering these new lines
of evidence reveals the critical role of mast cells in the ﬁne-tuned modulation of both homeo-
static and inﬂammatory responses, and extends new avenues of research into their functions,
beyond their role in allergic responses through the release of histamine and other mediators
(see Outstanding Questions).
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